TruScreen Limited has announced that it has entered into a collaborative program to screen 100,000 women in the Peoples Republic of China.
The program is a joint initiative between the China Doctors Association, Beijing SiweiXiangtai Tech Co Ltd (a principal distributor of TruScreen’s products in China), and TruScreen.
The screening programme will be led by Professor Zhang Zhenyu from the Beijing Chaoyang Hospital. Covering every province in China the program will involve 100 hospitals and 1,000 patients per hospital. This particular programme will utilise 100,000 single use sensors (“SUS”). TruScreen anticipates that this particular programme will generate approximately NZ$860,000 of disposable Single Use Sensor (SUS) revenues to TruScreen over the course of the next 12- 14 month period.
TruScreen’s objective is to leverage off this programme and extend the reach, scope and volume of women being screened in respect of this particular programme over time.
This is the first of the major programs that are expected to be announced by TruScreen following its gaining of China Food and Drug Administration (CFDA) regulatory approval on April 30, 2015.
This programme represents just one of many prospective distribution channels for TruScreen’s product in China. TruScreen is working hard with its distribution partners in China to develop a significant network of similar screening programmes throughout China and a number of other international jurisdictions.
TruScreen CEO Martin Dillon estimates the Chinese cervical cancer screening market to be worth an estimated $1bn per annum.